POLYPEPTIDES FROM NON-TYPEABLE HAEMOPHILUS INFLUENZAE
Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae , such as otitis media.
1 . An isolated, immunogenic polypeptide comprising an amino acid sequence with at least 85% sequence identity to the sequence of SEQ ID NO:3834.
2 . The polypeptide of claim 1 , wherein said polypeptide comprises an amino acid sequence with at least 90% sequence identity to the sequence of SEQ ID NO:3834.
3 . The polypeptide of claim 1 , wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:3834.
4 . A composition comprising: (a) the polypeptide of claim 1 ; and (b) a pharmaceutically acceptable carrier.
5 . A composition comprising: (a) the polypeptide of claim 2 ; and (b) a pharmaceutically acceptable carrier.
6 . A composition comprising: (a) the polypeptide of claim 3 ; and (b) a pharmaceutically acceptable carrier.
7 . The composition of claim 4 , further comprising an adjuvant.
8 . The composition of claim 5 , further comprising an adjuvant.
9 . The composition of claim 6 , further comprising an adjuvant.
10 . A method of treating or preventing a Haemophilus influenzae infection in a patient, comprising administering to the patient a therapeutically effective amount of the composition of claim 4 .
11 . A method of treating or preventing a Haemophilus influenzae infection in a patient, comprising administering to the patient a therapeutically effective amount of the composition of claim 5 .
12 . A method of treating or preventing a Haemophilus influenzae infection in a patient, comprising administering to the patient a therapeutically effective amount of the composition of claim 6 .
13 . A method of treating or preventing a Haemophilus influenzae infection in a patient, comprising administering to the patient a therapeutically effective amount of the composition of claim 7 .
14 . A method of treating or preventing a Haemophilus influenzae infection in a patient, comprising administering to the patient a therapeutically effective amount of the composition of claim 8 .
15 . A method of treating or preventing a Haemophilus influenzae infection in a patient, comprising administering to the patient a therapeutically effective amount of the composition of claim 9 .
16 . The method of claim 10 , wherein the H. influenzae infection is caused by a non-typeable H. influenzae.
17 . The method of claim 11 , wherein the H. influenzae infection is caused by a non-typeable H. influenzae.
18 . The method of claim 12 , wherein the H. influenzae infection is caused by a non-typeable H. influenzae.
19 . The method of claim 13 , wherein the H. influenzae infection is caused by a non-typeable H. influenzae.
20 . The method of claim 14 , wherein the H. influenzae infection is caused by a non-typeable H. influenzae.
21 . The method of claim 15 , wherein the H. influenzae infection is caused by a non-typeable H. influenzae.
22 . A nucleic acid molecule comprising a nucleotide sequence encoding the polypeptide of claim 1 .
23 . A nucleic acid molecule comprising a nucleotide sequence encoding the polypeptide of claim 2 .
24 . A nucleic acid molecule comprising a nucleotide sequence encoding the polypeptide of claim 3 .
25 . A recombinant vector comprising the nucleic acid molecule of claim 22 .
26 . A recombinant vector comprising the nucleic acid molecule of claim 23 .
27 . A recombinant vector comprising the nucleic acid molecule of claim 24 .
28 . A host cell comprising the recombinant vector of claim 25 .
29 . A host cell comprising the recombinant vector of claim 26 .
30 . A host cell comprising the recombinant vector of claim 27 .